Skip to main content
Midas Edge

Raphael Pharmaceutical Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

RAPHStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

CONSOLIDATED STATEMENTS OF CHANGES STOCKHOLDERS’ IN EQUITY (DEFICIT)

Common stock · Additional paid-in · Receivable on account of · Accumulated · Total
Number · Amount · capital · shares · deficit · equity
Balance as of January 1, 202418,502,918$185$7,392$(100)$(7,370)**$107**
Issuance of common stock and warrants158,5002178100-280
Issuance of common stock in exchange for services40,000(*40--40
Share based compensation expenses--350--350
Net loss----(1,519)(1,519)
Balance as of December 31, 202418,701,418187$7,960$-$(8,889)$(742)
Common stock · Additional paid-in · Receivable on account of · Accumulated · Total
Number · Amount · capital · shares · deficit · equity
Balance as of January 1, 202518,701,418$187$7,960$-$(8,889)$(742)
Issuance of common stock and warrants1,125,00011332--343
Issuance of common stock in exchange for services--0
Share based compensation expenses350,0004241--245
Net loss----(1,279)(1,279)
Balance as of December 31, 202520,176,418202$8,533$-$(10,168)$(1,433)
(*)less than 1 thousand.

The accompanying notes are an integral part of the consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.